Dr Andrew Rut in PharmaTimes magazine - January 2021
How can pharma help drive COVID-19 vaccination adherence?
The authorisation of Pfizer/BioNTech, Moderna and now Oxford/AstraZeneca COVID-19 vaccines has brought much needed hope in the face of rapidly rising COVID-19 infection rates around the world. It is a truly remarkable achievement that the pharmaceutical industry has transformed its drug discovery and development to launch vaccines in less than 12 months and deliver headline efficacy rates of circa 95%.
However, market authorisation is simply one leg in a relay race. The next stage will be managing the wave of information requests and safety reports that must be expected as part of the COVID-19 mass vaccination campaigns...
